Taiwan Bio Therapeutics (ROCO:6892) Long-Term Debt: NT$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
14 GF Score
Price NT$26.20
GF Value NT$14.57
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics Long-Term Debt?

Taiwan Bio Therapeutics ROCO:6892 +6.50% 14 Long-Term Debt is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 14/100 and a GF Value™ of NT$14.57 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Taiwan Bio Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

Taiwan Bio Therapeutics  (ROCO:6892) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Taiwan Bio Therapeutics Long-Term Debt Related Terms

Taiwan Bio Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Long-Term Debt Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6892
14GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$0.0 Mil mean?
Taiwan Bio Therapeutics (ROCO:6892) has a Long-Term Debt of NT$0.0 Mil as of Dec. 2025.
Is Taiwan Bio Therapeutics' Long-Term Debt too high?
Taiwan Bio Therapeutics' current Long-Term Debt is NT$0.0 Mil. Overall, Taiwan Bio Therapeutics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Long-Term Debt compare to VRTX and REGN?
Taiwan Bio Therapeutics' Long-Term Debt of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Taiwan Bio Therapeutics's current Long-Term Debt is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.57, compared to a current price of NT$26.20 — trading 79.8% above its estimated fair value. The current Long-Term Debt is NT$0.0 Mil. Taiwan Bio Therapeutics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Long-Term Debt is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$26.20 is trading 79.8% above its estimated GF Value™ of NT$14.57. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • Long-Term Debt: NT$0.0 Mil
  • GF Value™: NT$14.57 vs. price of NT$26.20 (79.8% above fair value)
  • GF Score™: 14/100 with 5 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
14GF Score

Get the complete analysis for ROCO:6892

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.20
Price
NT$14.57
GF Value